Skip to main content
Evidence Snapshot

Fibroblast growth factor receptor 4

CHEMBL3973 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:30Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3973
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Fibroblast growth factor receptor 4 as ChEMBL target CHEMBL3973, mapped to UniProt P22455. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Fibroblast growth factor receptor 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3973
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P22455
Fibroblast growth factor receptor 4
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Fibroblast growth factor receptor 4 matters

As of 2026-09-14

Fibroblast growth factor receptor 4 is reviewed as Fibroblast growth factor receptor 4 (UniProt P22455); Fibroblast growth factor receptor 4 shows clinical signal disease relevance led by cancer. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 16 approved drugs, 3760 compounds, and 736 assays, with lead potency reaching pChEMBL 10.0.

Disease context
cancer

Fibroblast growth factor receptor 4 shows clinical signal disease relevance led by cancer. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include FGF401.

Start review with cancer because it currently carries clinical signal support. Linked drugs include FGF401. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 3760 compounds, and 736 assays for this target. The dominant activity type is IC50. CHEMBL3948579 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL3948579 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Fibroblast growth factor receptor 4 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P22455, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3760
Total Compounds
736
Total Assays
16
Approved Drugs
IC50: 4727.0, KI: 12.0, EC50: 4.0, KD: 159.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3948579
 10.0 IC50 —
No preferred name
CHEMBL3912731
 9.7 IC50 —
No preferred name
CHEMBL3912896
 9.7 IC50 —
No preferred name
CHEMBL3968338
 9.7 IC50 —
No preferred name
CHEMBL4786195
 9.7 IC50 —

Approved Drugs

Structure Compound First Approval
FUTIBATINIB
CHEMBL3701238
 2022
INFIGRATINIB
CHEMBL1852688
 2021
INFIGRATINIB PHOSPHATE
CHEMBL1834657
 2021
PEMIGATINIB
CHEMBL4297522
 2020
ERDAFITINIB
CHEMBL3545376
 2019
BRIGATINIB
CHEMBL3545311
 2017
LENVATINIB
CHEMBL1289601
 2015
NINTEDANIB ESYLATE
CHEMBL3039504
 2014
NINTEDANIB
CHEMBL502835
 2014
CERITINIB
CHEMBL2403108
 2014
PONATINIB
CHEMBL1171837
 2012
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:30Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3973